New combo therapy shows promise for rare adrenal cancer
NCT ID NCT05036434
First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study tests a combination of two drugs, pembrolizumab and lenvatinib, in 30 adults with advanced adrenal cancer that has not responded to standard chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease. Participants receive the drugs intravenously and by mouth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
Conditions
Explore the condition pages connected to this study.